Table I.

Hemological alterations in mice bearing similar ssIL-1β- or mock-transfected tumor burdensa

NormalMockssIL-1β
Tumor
 Days after injection22–2313–14
 Diameter14.9 ± 0.414.5 ± 0.3
Peripheral blood
 RBC(×106/μl)7.01 ± 0.435.93 ± 2.783.84 ± 0.51b
 WBC(×103/μl)6.18 ± 0.275.75 ± 0.5349.67 ± 2.75b,c
 CD11b+/Gr-1+ (%)6.20 ± 1.239.30 ± 2.4344.30 ± 3.34b,c
Spleen
 Weight (g)0.12 ± 0.010.2 ± 0.010.38 ± 0.02b,c
 CD11b+/Gr-1+ (%)2.71 ± 0.603.16 ± 0.5326.80 ± 2.31b,c
CFU-Cs
 Blood (1 × 106)15.0 ± 3.511.7 ± 4.464.3 ± 2.8b
 Spleen (1× 106)126.0 ± 3.5119.0 ± 3.0279.0 ± 15.1b
 Bone marrow (5× 104)92.0 ± 4.099.3 ± 14.339 ± 6.9b
Serum IL-1β (ng/ml)1.8 ± 0.3
T cell proliferation (%)100105 ± 1.515 ± 2.5bc
  • a Mock-transfected tumor cells were injected i.f.p. 10 days before the injection of ssIL-1β-transfected cells (2 × 105/mouse). Twenty-two to 23 days and 13–14 days after injection of mice with control tumor cells and ssIL-1β-transfected cells, respectively, the tumor size in both groups of tumor-bearing mice was similar (around 15 mm), indicating a similar tumor burden. In these mice, hemological parameters, numbers of granulocyte/macrophage CFU-Cs in the blood, spleen and bone marrow, systemic IL-1β levels and Con A-induced T cell proliferation were assessed as described in Materials and Methods.

  • b A value of p < 0.01, vs the group of normal mice.

  • c A value of p < 0.01, vs the group of mice bearing tumors induced by mock-transfected cells.